#Japan #AI Solutions #Osaka #GramEye #AMR Crisis

GramEye Funding Announcement

GramEye Inc., headquartered in Ibaraki, Osaka, has successfully completed a Series B funding round, raising a total of 570 million yen. This round was spearheaded by Beyond Next Ventures, with continued contributions from existing investors such as Samurai Incubate Inc. and NES Inc. This new influx of capital increases their total funding to 1.65 billion yen when combined with prior grants, including 4.2 billion yen received from the NEDO PCA program.

Purpose of the Funding

In January 2025, GramEye introduced its AI-driven, fully automated Gram-staining robotics solution, which is already in use in clinical laboratories. User feedback has driven continuous enhancements to the AI capabilities and hardware design of their products. The latest funding will be utilized to further fortify these existing product features, advance their global market presence—including obtaining FDA approval for their devices in the United States—and develop a next-generation Clinical Decision Support System (CDSS).

The CDSS aims to support healthcare professionals by providing rapid, evidence-based information for effective antibiotic selection and decision-making. By implementing this system, GramEye is dedicated to promoting judicious antimicrobial use, improving infection control measures, and ultimately enhancing global public health outcomes.

Strengthening Recruitment Across Business Divisions

To support its ambitious growth plans, GramEye is expanding its hiring across multiple divisions, actively seeking experienced professionals for critical roles. Positions include:

• - Core Business Executives (CSO/COO)
• - Sales Executives for regions such as China and Kanto
• - Mechanical Design Engineers for the Automated Gram-staining System
• - Mechanical and Electrical Engineers for New AI Projects
• - Project Managers for Infectious Disease Decision Support AI/SaMD Development

For interested candidates, recruitment details can be found on their official website.

Investor Comments

Beyond Next Ventures

Katsuya Hashizume, Executive Officer & Partner, remarked, "Antimicrobial resistance (AMR) presents a pressing global health and societal challenge impacting populations worldwide. GramEye is exceptionally positioned to revolutionize infectious disease care utilizing AI and robotics, and we are confident in their leadership under Dr. Hiraoka and Dr. Yamada."

Samurai Incubate Inc.

Yoshitaka Kai, Partner, expressed excitement over their renewed investment, stating, "GramEye's Mycrium product automates a critical process in Gram staining, expediting infectious-disease care and promoting proper antibiotic use. We are committed to supporting their ongoing innovation against the AMR crisis."

NES Inc.

Nobuhiro Imagawa, General Partner, noted the progress since the prior Series A funding, highlighting GramEye's developments in medical device certification and clinical implementation of Mycrium. He reaffirmed commitment to supporting GramEye’s international expansion and new product development focused on combating antibiotic-resistant bacteria.

Company Vision

GramEye is on a mission to transform infectious disease diagnostics and emerge as a leader in addressing the global antimicrobial resistance (AMR) crisis. Utilizing advanced AI technology, they aim to optimize the speed and accuracy of infection diagnostics. The World Health Organization (WHO) recognizes the AMR crisis as one of the most urgent global health issues today, alongside climate change. Millions succumb annually due to complications arising from resistant infections.

Through their innovative technologies, GramEye strives to facilitate judicious antibiotic use, reduce mortality rates associated with AMR, and mitigate worldwide economic losses attributed to this crisis.

Company Overview

• - Company Name: GramEye Inc.
• - Founded: May 18, 2020
• - CEO: Yu Hiraoka
• - Headquarters: 3-7-1 Ekimae, Ibaraki, Osaka, Japan
• - Business: Development of AI-powered automated Gram-staining medical devices
• - Website: GramEye Official

In conclusion, the recent funding and strategic initiatives underline GramEye's dedication not only to innovation but also to addressing critical health challenges globally. As the company advances in its mission, it promises to play a pivotal role in the future of infectious disease management, assuring a safer, healthier world for all.